Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew W Roberts

Showing results (11-20 of 198) with videos related to

Pageof 20
Sort By:
Cancer Discovery|August 3, 2019
Polyclonal Heterogeneity: The New Norm for Secondary Clinical Resistance to Targeted Monotherapy in Relapsed Leukemia?Andrew H Wei, Andrew W Roberts
Nature Reviews. Rheumatology|December 4, 2015
Targeting GM-CSF in inflammatory diseasesIan P Wicks, Andrew W Roberts
Leukemia & Lymphoma|April 10, 2008
Bortezomib: putting mantle cell lymphoma on death rowAndrew H Wei, Andrew W Roberts
Hemasphere|June 12, 2023
BCL2 Inhibition: A New Paradigm for the Treatment of AML and BeyondAndrew H Wei, Andrew W Roberts
Psychiatric Services (Washington, D.C.)|May 9, 2018
Buprenorphine Use and Spending for Opioid Use Disorder Treatment: Trends From 2003 to 2015Andrew W Roberts, Brendan Saloner, Stacie B Dusetzina
Journal of Comparative Effectiveness Research|January 8, 2015
Revisiting the washout period in the incident user study design: why 6-12 months may not be sufficientAndrew W Roberts, Stacie B Dusetzina, Joel F Farley
Methods in Molecular Biology (Clifton, N.J.)|January 21, 2012
Towards a four-dimensional view of neutrophilsBen A Croker, Andrew W Roberts, Nicos A Nicola
American Journal of Public Health|October 8, 2016
Lock-In Programs and the Opioid Epidemic: A Call for EvidenceAndrew W Roberts, Walid F Gellad, Asheley Cockrell Skinner
The New England Journal of Medicine|June 2, 2016
New Agents to Treat Chronic Lymphocytic LeukemiaAndrew W Roberts, Matthew S Davids, John F Seymour
Seminars in Oncology|April 5, 2016
Progress in BCL2 inhibition for patients with chronic lymphocytic leukemiaConstantine S Tam, John F Seymour, Andrew W Roberts
Pageof 20

Showing results (11-20 of 198) with videos related to

Sort By:
Pageof 20
Cancer Discovery|August 3, 2019
Polyclonal Heterogeneity: The New Norm for Secondary Clinical Resistance to Targeted Monotherapy in Relapsed Leukemia?Andrew H Wei, Andrew W Roberts
Nature Reviews. Rheumatology|December 4, 2015
Targeting GM-CSF in inflammatory diseasesIan P Wicks, Andrew W Roberts
Leukemia & Lymphoma|April 10, 2008
Bortezomib: putting mantle cell lymphoma on death rowAndrew H Wei, Andrew W Roberts
Hemasphere|June 12, 2023
BCL2 Inhibition: A New Paradigm for the Treatment of AML and BeyondAndrew H Wei, Andrew W Roberts
Psychiatric Services (Washington, D.C.)|May 9, 2018
Buprenorphine Use and Spending for Opioid Use Disorder Treatment: Trends From 2003 to 2015Andrew W Roberts, Brendan Saloner, Stacie B Dusetzina
Journal of Comparative Effectiveness Research|January 8, 2015
Revisiting the washout period in the incident user study design: why 6-12 months may not be sufficientAndrew W Roberts, Stacie B Dusetzina, Joel F Farley
Methods in Molecular Biology (Clifton, N.J.)|January 21, 2012
Towards a four-dimensional view of neutrophilsBen A Croker, Andrew W Roberts, Nicos A Nicola
American Journal of Public Health|October 8, 2016
Lock-In Programs and the Opioid Epidemic: A Call for EvidenceAndrew W Roberts, Walid F Gellad, Asheley Cockrell Skinner
The New England Journal of Medicine|June 2, 2016
New Agents to Treat Chronic Lymphocytic LeukemiaAndrew W Roberts, Matthew S Davids, John F Seymour
Seminars in Oncology|April 5, 2016
Progress in BCL2 inhibition for patients with chronic lymphocytic leukemiaConstantine S Tam, John F Seymour, Andrew W Roberts
Pageof 20